AR059284A1 - Derivados de aminas secundarias - Google Patents

Derivados de aminas secundarias

Info

Publication number
AR059284A1
AR059284A1 ARP070100434A ARP070100434A AR059284A1 AR 059284 A1 AR059284 A1 AR 059284A1 AR P070100434 A ARP070100434 A AR P070100434A AR P070100434 A ARP070100434 A AR P070100434A AR 059284 A1 AR059284 A1 AR 059284A1
Authority
AR
Argentina
Prior art keywords
alkyl
formula
integer
ch2ch2
substituted
Prior art date
Application number
ARP070100434A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38006850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR059284A1 publication Critical patent/AR059284A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de éstos como ingredientes activos para la preparacion de composiciones farmacéuticas. También se refiere a aspectos relacionados que incluyen procedimientos ira la preparacion de los compuestos, composiciones farmacéuticas que contiene uno o más de estos compuestos y especialmente su uso como inhibidores de renina. Reivindicacion 1: Un compuesto de formula (1) en la cual la línea de puntos en el anillo Z que contiene nitrogeno de 6 miembros de formula (1) (dicho anillo Z consiste en los átomos de anillo numerados 1 a 6) indica que o bien está presente un enlace doble en la posicion 3,4- o 4,5- de el anillo Z de la formula (1) o no está presente ningun enlace doble en el anillo 7 de la formula (1); y donde si n = 0, puede estar presente un enlace doble en la posicion 3,4- o 4,5- del anillo Z de la formula (1); o si n = 1, puede estar presente un enlace doble en la posicion 3,4- del anillo Z de formula (1); o: no está presente en ningun enlace doble en el anillo Z de formula (1) si: i) n representa el numero entero 0 y X representa N o N+-O, o ii) n representa el numero entero 0 y V representa -O-CH2-Q-, o iii) n representa el numero entero 0, W representa fenilo para sustituido o piridinilo para sustituido y V representa un pirrolidinilo de la formula (2) o iv) n representa el numero entero 1 y L representa -CH2-CH2-, -CH2-CH(R5)-CH2-, -CH2-O-CH2-, o -CH2-S-CH2-, o v) n representa el numero entero 1, L representa -CH2-N(R6)-CH2-, y X representa N o N+-O-- ; -X representa CH, N, o N+-O-; W representa a fenilo para sustituido, piridinilo para sustituido o un tiazolilo; V representa -CH2CH2CH2-, -CH2CH2-A-, -CH2-A-CH2-, -A-CH2CH2-, -CH2CH2CH2CH2-, -A-CH2CH2CH2-, -CH2-A-CH2CH2-, -CH2CH2-A-CH2-, - CH2CH2CH2-A-, -A-CH2CH2-B-, -CH2CH2CH2CH2CH2, -A-CH2CH2CH2CH2-, -CH2-A-CH2CH2CH2-, -CH2CH2-A-CH2CH2, -CH2CH2CH2-A-CH2-, -CH2CH2CH2CH2-A-, -A-CH2CH2CH2-B-, -CH2-A-CH2CH2-B-, -A-CH2CH2-B-CH2, -A-CH2CH2CH2-B-CH2-, -CH2-A-CH2CH2CH2-B-, o -O-CH2-Q-, donde Q está unido al grupo U de formula (1); o: si i) n representa el numero entero 0, o ii) n representa el numero entero 1 y X representa N o N+-O--, o iii) L representa -CH2-CH2-, o iv) L representa -CH2-N(R6)-CH2-, y W representa un piridinilo para sustituido, V puede representar además un pirrolidinilo de la formula (2); U representa arilo no sustituido; arilo mono-, di-, tri- o tetra-sustituido, donde los sustituyentes están seleccionados independientemente alquilo C1-7, -CF3, halogeno e hidroxialquilo C1-7 o un heteroarilo de cinco miembros que contiene dos heteroátomos seleccionados independientemente entre nitrogeno, oxigeno y azufre, donde dicho radical heteroarilo está opcionalmente mono-, di- o trisustituido, donde los sustituyentes están seleccionados independientemente entre alquilo C1-7, alcoxi C1-7, -CF3, -OCF3, y halogeno; Q representa un heteroarilo de cinco miembros con dos o tres heteroátomos seleccionados independientemente entre O y N; L representa -CH2- CH2, -CH2-CH(R5)-CH2, -CH2-N(R6)-CH2-, -CH2-O-CH2-, o -CH2-S-CH2-; A y B representan independientemente entre otros -O- o -S-; R1 representa alquilo C1-7, o cicloalquilo; R2 representa halogeno o alquilo C1-7; R3 representa halogeno, alquilo C1-7, alcoxi C1-7, -CF3, o hidrogeno; R4 representa alquilo C1-7-O-(CH2)04-CH2; CF3-O-(CH2)0-4-CH2-; R'RöN-(CH2)0-4-CH2-, donde R' y Rö están seleccionados independientemente del grupo que consiste en hidrogeno, alquilo C1-7, (sustituido opcionalmente con uno a tres fluor), ciclopropilo (sustituido opcionalmente con uno a tres fluor), ciclopropilalquilo C1-7 (sustituido opcionalmente con uno a tres fluor), y -C(=O)-R'ö donde R'ö es alquilo C1-4, alcoxi C1-4, -CF3, -CH2-CF3, o ciclopropilo; o R12NH- C(=O)-(O)0-1-(CH2)0-4-, donde R12 es alquilo C1-4, alcoxi C1-4, o ciclopropilo; R5 representa -H, -CH2OR8, -CH2NR7R8, -CH2NR7COR8, -CH2NR7SO2R8, -CO2R8, -CH2OCONR7R8, -CONR7R8, -CH2NR7CONR7'R8, -CH2SO2NR7R8, -CH2SR8, - CH2SOR8, o -CH2SO2R8; R6 representa -R8, -COR8, -COOR10, -CONR7R8, -C(NR7)NR7'R8, -CSNR7R8, -SO2R8, o -SO2NR7R8; o R6 representa un radical de la formula: (3) o (4) donde T representa -CH2-, -NH- o -O-, m es un numero entero de 1 a 6 y r es un numero entero 1 a 4; R7 y R7' representan independientemente hidrogeno, alquilo C1-7, alquenilo C2-7, cicloalquilo o cicloalquilalquilo C1-7, donde alquilo C1-7, cicloalquilo y cicloalquilalquilo C1-7 pueden estar sustituidos con uno, dos o tres halogenos; R8 representa hidrogeno, alquilo C1-7, cicloalquilo, o cicloalquilalquilo C1-7 donde alquilo C1-7, cicloalquilo, o cicloalquilalquilo C1-7 pueden estar mono-, di- o trisustituidos donde los sustituyentes están seleccionados independientemente del grupo que consiste en halogeno, hidroxi, -OCOR11, -COOR11, alcoxi C1-7, ciano, SO2R11, -CONR11R11', morfolin-4-il-CO-, ((4-alquil C1-7)piperazin-1-il)-CO-, -NHC(NH)NH2, -NR9R9' y alquilo C1-7, con la condicion de que un átomo de carbono está unido a lo sumo a un heteroátomo en el caso de que este átomo de carbono esté sp3-hibridado; R9 y R9' representan independientemente hidrogeno, alquilo C1-7, cicloalquilo, cicloalquilalquilo C1-7, hidroxialquilo C1-7, -COOR7, o -CONH2; R10 representa halogeno, alquilo C1-7, alcoxi C1-7, -CF3, o hidrogeno; R11 y R11' representan independientemente hidrogeno, alquilo C1-7, alquenilo C2-7, cicloalquilo, o cicloalquilalquilo C1-7 donde alquilo C1-7, cicloalquilo, y cicloalquilalquilo C1-7 pueden estar sustituidos con uno, dos o tres halogenos; y n representa el numero entero 0 o 1; y sus sales.
ARP070100434A 2006-02-02 2007-02-01 Derivados de aminas secundarias AR059284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2006050356 2006-02-02

Publications (1)

Publication Number Publication Date
AR059284A1 true AR059284A1 (es) 2008-03-19

Family

ID=38006850

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100434A AR059284A1 (es) 2006-02-02 2007-02-01 Derivados de aminas secundarias

Country Status (16)

Country Link
US (1) US7968720B2 (es)
EP (1) EP1981847A1 (es)
JP (1) JP2009526767A (es)
KR (1) KR20080091273A (es)
CN (1) CN101379033A (es)
AR (1) AR059284A1 (es)
AU (1) AU2007210813A1 (es)
BR (1) BRPI0707349A2 (es)
CA (1) CA2637546A1 (es)
IL (1) IL193150A0 (es)
MA (1) MA30313B1 (es)
NO (1) NO20083738L (es)
NZ (1) NZ570828A (es)
RU (1) RU2425032C2 (es)
TW (1) TW200738714A (es)
WO (1) WO2007088514A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786814B1 (en) * 2004-08-25 2010-03-31 Actelion Pharmaceuticals Ltd. Bicyclononene derivatives as renin inhibitors
RU2410374C2 (ru) * 2005-05-27 2011-01-27 Актелион Фармасьютикалз Лтд Новые амидные производные пиперидинкарбоновой кислоты
WO2007088514A1 (en) 2006-02-02 2007-08-09 Actelion Pharmaceuticals Ltd Secondary amines as renin inhibitors
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
US8343968B2 (en) 2007-05-24 2013-01-01 Merck Canada Inc. Case of renin inhibitors
US8334308B2 (en) 2007-08-20 2012-12-18 Merck Sharp & Dohme Corp. Renin inhibitors
BRPI0912388A2 (pt) * 2008-05-05 2017-09-26 Merck Frosst Canada Ltd composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças
WO2010011584A2 (en) * 2008-07-25 2010-01-28 Merck & Co., Inc. Process for making a renin inhibitor
WO2013084241A1 (en) 2011-12-09 2013-06-13 Cadila Healthcare Limited Compounds as inhibitors of renin
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
DK0863875T3 (da) 1995-09-07 2003-12-01 Hoffmann La Roche Hidtil ukendte 4-(oxyalkoxyphenyl)-3-oxy-piperiner til behandling af hjerte- og nyrelidelser
US5994294A (en) 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
JP2001504457A (ja) 1996-11-01 2001-04-03 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
JP4041123B2 (ja) 2002-04-29 2008-01-30 アクテリオン ファマシューティカルズ リミテッド 新規なジアザビシクロノネン
PL375214A1 (en) 2002-06-27 2005-11-28 Actelion Pharmaceuticals Ltd. Novel tetrahydropyridine derivatives as renin inhibitors
CA2521932A1 (en) 2003-04-29 2004-11-11 Actelion Pharmaceuticals Ltd Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives
CA2521938A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors
RU2005137184A (ru) 2003-04-30 2006-03-20 Актелион Фармасьютикалз Лтд. (Ch) Новые производные тропана
WO2004096803A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives
CA2540782A1 (en) 2003-10-13 2005-05-06 Olivier Bezencon Diazabicyclononene derivatives and their use as renin inhibitors
EP1786814B1 (en) 2004-08-25 2010-03-31 Actelion Pharmaceuticals Ltd. Bicyclononene derivatives as renin inhibitors
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
WO2006079988A1 (en) 2005-01-28 2006-08-03 Actelion Pharmaceuticals Ltd 7- {4- [2- (2 , 6-dichl0r0-4-methylphen0xy) ethoxy] phenyl}-3 , 9-diazabicyclo [3 .3 . 31] non - 6-ene- s- carboxylic acid cyclopropyl- (2 , 3-dimethylbenzyd amide as inhibitors of renin for the treatment of hypertension
RU2410374C2 (ru) 2005-05-27 2011-01-27 Актелион Фармасьютикалз Лтд Новые амидные производные пиперидинкарбоновой кислоты
WO2007088514A1 (en) 2006-02-02 2007-08-09 Actelion Pharmaceuticals Ltd Secondary amines as renin inhibitors
US20090062342A1 (en) * 2006-03-08 2009-03-05 Actelion Pharmaceuticals Ltd. Amines

Also Published As

Publication number Publication date
US7968720B2 (en) 2011-06-28
RU2008135458A (ru) 2010-03-10
CA2637546A1 (en) 2007-08-09
AU2007210813A1 (en) 2007-08-09
JP2009526767A (ja) 2009-07-23
BRPI0707349A2 (pt) 2011-05-03
EP1981847A1 (en) 2008-10-22
WO2007088514A1 (en) 2007-08-09
NO20083738L (no) 2008-10-14
NZ570828A (en) 2011-07-29
IL193150A0 (en) 2009-02-11
TW200738714A (en) 2007-10-16
KR20080091273A (ko) 2008-10-09
MA30313B1 (fr) 2009-04-01
RU2425032C2 (ru) 2011-07-27
US20090176823A1 (en) 2009-07-09
CN101379033A (zh) 2009-03-04

Similar Documents

Publication Publication Date Title
AR059284A1 (es) Derivados de aminas secundarias
AR059886A1 (es) Derivados de amidas como inhibidores de renina
AR067691A1 (es) Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas.
AR112682A1 (es) Compuestos herbicidas
ECSP088805A (es) 2-(piridin-2-il)-pirimidinas como fungicidas
CO6420344A2 (es) Derivados de triazolopiridina como inhibidores de proteínas cinasas activadas por mitogeno p38 (map)
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
ECSP12012212A (es) Derivados de ariletinilo
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
CO6341575A2 (es) Combinaciones que comprenden metotrexato e inhibidores de dhodh
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR110498A1 (es) DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR060334A1 (es) Derivados de benzimidazol
AR120982A1 (es) Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre
AR059722A1 (es) Aminas inhibidoras de renina. composiciones farmaceuticas y usos.
AR111672A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
AR052055A1 (es) Derivados de biciclononeno
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
AR066576A1 (es) Nuevos derivados de pirazolona
AR078683A1 (es) Compuesto de pirona y su uso para el control de plagas
AR054418A1 (es) Quinazolinas pirazolamino sustituidas. procesos de obtencion y composiciones farmaceuticas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal